Respiratory Administration of Infliximab Dry Powder for Local Suppression of Inflammation

Respiratory Administration of Infliximab Dry Powder for Local Suppression of Inflammation Publisher Pubmed

Faghihi H¹ ; Najafabadi AR¹ ; Daman Z¹ ; Ghasemian E¹ ; Montazeri H² ; Vatanara A^{1, 3}

Show Affiliations

1. Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, 14155-6451, Iran
2. School of Pharmacy-International Campus, Iran University of Medical Sciences, Tehran, 1449614535, Iran
3. Aerosol Research Laboratory, Department of Pharmaceutics, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Source: AAPS PharmSciTech Published:2019

Abstract

The airways are verified as a relevant route to improve antibody therapeutic index with superior lung concentration but limited passage into systemic blood stream. The current research aimed to process spray-dried (SD) powder of Infliximab to assess the feasibility of respiratory delivery of antibody for local suppression of lung-secreted tumor necrosis factor α (TNFα). Molecular and structural stability of powders were determined through size exclusion chromatography (SEC-HPLC) and Fourier transform infrared (FTIR) spectroscopy. Particle properties were characterized by laser light scattering, twin stage impinger (TSI), and scanning electron microscopy (SEM). In vitro biological activity was quantified applying L-929 cell line. Ovalbumin (OVA)-challenged balb/c mice were employed to evaluate the anti-TNFα activity of antibody formulation as in vivo experimental model. SD sample consisting of 36 mg trehalose, 12 mg cysteine, and 0.05% of Tween 20 was selected with minimum aggregation/fragmentation rate constants of 0.07 and 0.05 (1/month) based on 1 and 2 months of storage at 40°C and relative humidity of 75%. Fine particle fraction (FPF) value of this formulation was 67.75% with desired particle size and surface morphology for respiratory delivery. EC 50 was 8.176 and 6.733 ng/ml for SD Infliximab and Remicade®, respectively. SD antibody reduced TNFα (26.56 pg/ml) secretion in mouse lung tissue, more than 2 orders of magnitudes comparing positive control group (TNFα, 68.34 pg/ml). The success of antibody inhalation mainly depended on the spray drying condition, formulation components, and stability of antibody within aerosolization. Inhaled Infliximab could be a potential drug for local inhibition of lung inflammation. © 2019, American Association of Pharmaceutical Scientists.

Related Docs

View other Related Docs

1. Application of Cyclodextrins in Antibody Microparticles: Potentials for Antibody Protection in Spray Drying, Drug Development and Industrial Pharmacy (2017)

2. Application of Disaccharides Alone and in Combination, for the Improvement of Stability and Particle Properties of Spray-Freeze Dried Igg, Pharmaceutical Development and Technology (2019)

3. Amino Acid-Based Stable Adalimumab Formulation in Spray Freeze-Dried Microparticles for Pulmonary Delivery, Journal of Drug Delivery Science and Technology (2019)

4. Recent Progress in Drying Technologies for Improving the Stability and Delivery Efficiency of Biopharmaceuticals, Journal of Pharmaceutical Investigation (2023)

5. Drying Technologies for the Stability and Bioavailability of Biopharmaceuticals, Pharmaceutics (2018)

6. Poly(Lactic Acid)/Poly(Lactic-Co-Glycolic Acid) Particulate Carriers for Pulmonary Drug Delivery, Journal of Pharmaceutical Investigation (2019)

7. Optimization of a Dry Powder Inhaler of Ciprofloxacin-Loaded Polymeric Nanomicelles by Spray Drying Process, Pharmaceutical Development and Technology (2019)

8. Spray-Freeze Drying: A Suitable Method for Aerosol Delivery of Antibodies in the Presence of Trehalose and Cyclodextrins, AAPS PharmSciTech (2018)

Experts (# of related papers)

View all Related Experts

Alireza Vatanara (12)

Abdolhossein Rouholamini Najafabadi (4)

Style	Citing Format
MLA	Faghihi H, et al.. "Respiratory Administration of Infliximab Dry Powder for Local Suppression of Inflammation." AAPS PharmSciTech, vol. 20, no. 3, 2019, pp. -.
APA	Faghihi H, Najafabadi AR, Daman Z, Ghasemian E, Montazeri H, Vatanara A (2019). Respiratory Administration of Infliximab Dry Powder for Local Suppression of Inflammation. AAPS PharmSciTech, 20(3), -.
Chicago	Faghihi H, Najafabadi AR, Daman Z, Ghasemian E, Montazeri H, Vatanara A. "Respiratory Administration of Infliximab Dry Powder for Local Suppression of Inflammation." AAPS PharmSciTech 20, no. 3 (2019): -.
Harvard	Faghihi H et al. (2019) 'Respiratory Administration of Infliximab Dry Powder for Local Suppression of Inflammation', AAPS PharmSciTech, 20(3), pp. -.
Vancouver	Faghihi H, Najafabadi AR, Daman Z, Ghasemian E, Montazeri H, Vatanara A. Respiratory Administration of Infliximab Dry Powder for Local Suppression of Inflammation. AAPS PharmSciTech. 2019;20(3):-.
BibTex	@article{ author = {Faghihi H and Najafabadi AR and Daman Z and Ghasemian E and Montazeri H and Vatanara A}, title = {Respiratory Administration of Infliximab Dry Powder for Local Suppression of Inflammation}, journal = {AAPS PharmSciTech}, volume = {20}, number = {3}, pages = {-}, year = {2019} }
RIS	TY - JOUR AU - Faghihi H AU - Najafabadi AR AU - Daman Z AU - Ghasemian E AU - Montazeri H AU - Vatanara A TI - Respiratory Administration of Infliximab Dry Powder for Local Suppression of Inflammation JO - AAPS PharmSciTech VL - 20 IS - 3 SP - EP - PY - 2019 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract